Journal of advanced research · 2026
Rhein inhibits respiratory syncytial virus entry by stabilizing the prefusion conformation of the fusion protein.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Kunhuan, Xiong Yingcai, Song Junxi, Zhang Zhaowei, Tao Keyu, Yang Zepeng, Li Tao, Cai Liangyu, Ji Jianjian
Аннотация
INTRODUCTION: Respiratory syncytial virus (RSV) remains a major cause of severe lower respiratory tract infections. The high mutability of its RNA genome necessitates novel therapeutics, with the viral fusion (F) protein representing a promising target.
OBJECTIVES: This study aimed to identify RSV F protein inhibitors via structure-based virtual screening and to systematically characterize their antiviral efficacy and mechanism of action.
METHODS: A multi-tiered virtual screening of an antiviral compound library was performed against the prefusion RSV F protein structure. Hits were validated for binding using MST and SPR. The mechanism was elucidated through time-of-addition, membrane fusion, and lentiviral pseudotype assays. In vivo efficacy was evaluated in an RSV infected BALB/c mouse model.
RESULTS: Screening identified 10 candidate compounds to interact with RSV F protein. Among these, Rhein bound to the prefusion F protein with micromolar affinity. Rhein exhibited potent anti-RSV efficacy with IC50 values of 498.4 nM in HEp-2 cells and 594.0 nM in A549 cells. Further experiments revealed Rhein disrupted RSV membrane fusion by enhancing the conformational stability of the RSV F protein before fusion. Rhein bound to key residues within the central cavity of the RSV F protein at VAL406 and PHE137. Moreover, Rhein demonstrated potent inhibition against the K394R and K272E mutant pseudoviruses, indicating its potential efficacy against RSV variants resistant to Palivizumab and clinical-stage fusion inhibitors. Additionally, acute toxicity and pharmacokinetic studies revealed that Rhein has an LD50 > 2000 mg/kg, along with favorable oral absorption, extensive tissue distribution, and exposure kinetics suitable for antiviral intervention. In an in vivo study, Rhein was shown to alleviate RSV-induced pulmonary pathology by reducing viral titers, mitigating lung injury, and suppressing the inflammatory responses in the lungs.
CONCLUSION: Rhein is a promising RSV fusion inhibitor, and its unique binding mode offers a valuable lead compound for overcoming drug resistance.
OBJECTIVES: This study aimed to identify RSV F protein inhibitors via structure-based virtual screening and to systematically characterize their antiviral efficacy and mechanism of action.
METHODS: A multi-tiered virtual screening of an antiviral compound library was performed against the prefusion RSV F protein structure. Hits were validated for binding using MST and SPR. The mechanism was elucidated through time-of-addition, membrane fusion, and lentiviral pseudotype assays. In vivo efficacy was evaluated in an RSV infected BALB/c mouse model.
RESULTS: Screening identified 10 candidate compounds to interact with RSV F protein. Among these, Rhein bound to the prefusion F protein with micromolar affinity. Rhein exhibited potent anti-RSV efficacy with IC50 values of 498.4 nM in HEp-2 cells and 594.0 nM in A549 cells. Further experiments revealed Rhein disrupted RSV membrane fusion by enhancing the conformational stability of the RSV F protein before fusion. Rhein bound to key residues within the central cavity of the RSV F protein at VAL406 and PHE137. Moreover, Rhein demonstrated potent inhibition against the K394R and K272E mutant pseudoviruses, indicating its potential efficacy against RSV variants resistant to Palivizumab and clinical-stage fusion inhibitors. Additionally, acute toxicity and pharmacokinetic studies revealed that Rhein has an LD50 > 2000 mg/kg, along with favorable oral absorption, extensive tissue distribution, and exposure kinetics suitable for antiviral intervention. In an in vivo study, Rhein was shown to alleviate RSV-induced pulmonary pathology by reducing viral titers, mitigating lung injury, and suppressing the inflammatory responses in the lungs.
CONCLUSION: Rhein is a promising RSV fusion inhibitor, and its unique binding mode offers a valuable lead compound for overcoming drug resistance.